About Verastem

Management Team

Robert Forrester, LL.B., President/Chief Executive Officer

Mr. Forrester has 14 years of experience as the CEO, COO or CFO of both private and public life science companies with Forma Therapeutics, CombinatoRx (NASDAQ: CRXX, now ZLCS) and Coley (NASDAQ: COLY, acquired by Pfizer). Robert was a managing director of the Proprietary Investment Group at MeesPierson, part of the Fortis Group, investing in life science companies. Prior to MeesPierson, Robert worked for the investment banks, BZW (now Barclays Capital) and UBS, in the corporate finance groups undertaking M&A, and public and private finance transactions. Robert started his career as lawyer with Clifford Chance in London and Singapore. Robert has completed over $12 billion of transactions and holds a LL.B. from Bristol University.

Top of Page

Lou Vaickus, MD, FACP, Interim Chief Medical Officer

Prior to joining Verastem, Dr. Vaickus recently completed a 17-month appointment as interim CMO of InVivo Therapeutics. He served as VP and Head of Clinical Development at Vertex Pharmaceuticals where he supervised medical, biometrics, clinical operations, and outsourcing for Incivek® in hepatitis C; Kalydeco┬«, Orkambi┬«, and VX-661 for cystic fibrosis; and VX-970 and VX-803 in solid tumor indications. From 2002-2011, Dr. Vaickus was CMO of Tolerx, Inc., developing monoclonal antibodies for autoimmune indications and oncology, including a checkpoint inhibitor. From 1998-2002, he was Senior VP, Medical Affairs and R&D at Sunovion, where he supervised Phase 1–4 clinical trials, regulatory submissions, and medical marketing for Xopenex®, Brovana®, Lunesta®, and others. From 1993-1998, he was Medical Director of Oncology/Immunology at EMD Serono and supervised clinical and medical affairs for Rebif®. Dr. Vaickus has held faculty positions at the U of Iowa (Division of Hematology/Oncology) and at Roswell Park Cancer Institute/SUNY Buffalo (Divisions of Clinical Immunology, Bone Marrow Transplant, Hematologic Malignancies, and Solid Tumor Oncology and Investigational Therapeutics). He completed postdoctoral fellowships in hematology, oncology, and immunology at the Mayo Clinic and Stanford University. Dr. Vaickus has attained board certifications in internal medicine, hematology/hematologic malignancies, and medical oncology and received his MD from Loyola University's Stritch School of Medicine in Chicago. Dr. Vaickus is Founder and President of akta Pharmaceutical Development LLC™ (aktaPD), an open architecture consortium of experts who serve as comprehensive product development consultants with a focus in oncology, immunology, respiratory, and neurology indications.

Top of Page

Jack Green, Chief Financial Officer

Mr. Green was a key member of the senior management team for On-Q-ity and oversaw the financial activities, planning, budgeting and management of commercial and banking relationships. Previously, Mr. Green was the Senior Vice President and Chief Financial Officer of GTC Biotherapeutics (formerly Genzyme Transgenics Corporation), which was spun out from Genzyme Corporation as a stand-alone public company. Mr. Green is a Certified Public Accountant (CPA) with over 30 years of financial experience, including 20 within the biotechnology industry. Mr. Green received a Master’s degree in business administration from Boston University Graduate School of Management and a Bachelor’s degree from the College of the Holy Cross.

Top of Page

Jonathan Pachter, Ph.D., Head of Research

Dr. Pachter brings over 25 years of experience in leading discovery and translational research for small molecule and monoclonal antibody anti-cancer therapeutics. He was previously Head of Cancer Biology at OSI Pharmaceuticals where his team was responsible for development of models of tumor cell EMT (epithelial-mesenchymal transition) and discovery of drugs disrupting this process. At OSI he advanced five small molecules into development for treatment of cancer, including OSI-906 – a selective IGF-1R/ insulin receptor kinase inhibitor which progressed to phase III clinical trials and OSI-027 – a selective mTOR kinase inhibitor. Prior to OSI, Dr. Pachter held positions of increasing responsibility at Schering-Plough where he progressed three agents into development including the monoclonal antibody robatumumab which advanced to phase II clinical evaluation in cancer patients. Dr. Pachter also made key contributions to the regulatory approval of temozolomide for treatment of glioblastoma. He is an author of over 50 peer-reviewed publications and inventor on numerous patents. Dr. Pachter did his postdoctoral work in Pharmacology at Yale University School of Medicine and he holds a Ph.D. from Baylor College of Medicine.

Top of Page

Dan Paterson, Chief Operating Officer

Mr. Paterson has over 25 years of experience in management roles at healthcare and biotechnology companies, including as CBO, COO and CEO, with specific expertise in oncology drug and diagnostic product development, business development and launch planning. Prior to his current role, he served as Chief Business Officer of Verastem. Mr. Paterson was the Co-founder and COO of On-Q-ity, a developer of technology to capture and analyze circulating tumor cells, and the founding CEO of The DNA Repair Company (merged to form On-Q-ity), which developed oncology-focused molecular diagnostics. Prior to that, Mr. Paterson was Head of Global Strategy for Specialty Market and Patient-Level Data at IMS Health, after playing a key role in the acquisition of PharMetrics by IMS Health as VP, Marketing and Corporate Development. While at PharMetrics, Mr. Paterson led the development of an innovative suite of pharmaceutical product launch tools that became the basis of the company’s product line.

Earlier in his career, Mr. Paterson was on the founding management team of CareTools, a healthcare information systems company, OnCare, an oncology physician practice management company with $100 million in annual revenue, and Axion, an oncology pharmaceutical and clinical service firm with an annual revenue of over $250 million when acquired by Bristol Myers Squibb. Prior to his involvement in industry Mr. Paterson led the clinical operations for a nationwide cancer cooperative group headquartered at the Dana Farber Cancer Institute. Mr. Paterson holds a B.A. in Biology from Boston University, and attended the Northeastern University Graduate Pharmacology program.

Top of Page

Steven Bloom, Vice President, Corporate Development

Steven Bloom joined Verastem in March 2014 and serves as Vice President of Corporate Development. His responsibilities include business development, commercial analysis and external relations. Prior to joining the company, Steve was Senior Vice President at Ziopharm Oncology (NASDAQ: ZIOP) where for 6 years he led business development and the commercial planning initiatives for a late stage oncology asset. Before joining Ziopharm, Steve was Senior Vice President for the health informatics company Pharmetrics and was part of the leadership team that sold the company to IMS Health in 2005. After leaving Eli Lilly in 2002 he joined the health technology company Inflexxion and built a commercial infrastructure for the start up organization. Steve spent the first 20 years of his career at Eli Lilly and Company in leadership roles in marketing, sales and corporate affairs.

Steve is a graduate of The College of Pharmacy at Notheastern University and is current an Adjunct Faculty member at the University of Rhode Island College of Pharmacy.

Top of Page